FibroGen, Inc (NASDAQ:FGEN) – Equities research analysts at Leerink Swann increased their FY2017 earnings per share estimates for shares of FibroGen in a report released on Thursday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will earn ($1.74) per share for the year, up from their prior estimate of ($1.91). Leerink Swann has a “Outperform” rating and a $82.00 price target on the stock. Leerink Swann also issued estimates for FibroGen’s Q4 2017 earnings at ($0.28) EPS, FY2018 earnings at ($2.14) EPS, FY2019 earnings at ($0.52) EPS, FY2020 earnings at $1.97 EPS and FY2021 earnings at $4.35 EPS.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/11/15/leerink-swann-comments-on-fibrogen-incs-fy2017-earnings-fgen.html.
A number of other equities research analysts also recently issued reports on FGEN. William Blair reissued an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, August 8th. Citigroup Inc. boosted their price objective on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. Mizuho reissued a “hold” rating and set a $61.00 price objective on shares of FibroGen in a research report on Thursday, November 9th. Finally, BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. FibroGen currently has a consensus rating of “Buy” and a consensus price target of $65.67.
Shares of FibroGen (FGEN) opened at $44.85 on Monday. FibroGen has a 1 year low of $19.25 and a 1 year high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its stake in shares of FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of FibroGen by 1.7% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock valued at $939,000 after acquiring an additional 474 shares during the period. Principal Financial Group Inc. raised its stake in shares of FibroGen by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after acquiring an additional 504 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after acquiring an additional 696 shares during the period. Finally, Tudor Investment Corp ET AL raised its stake in shares of FibroGen by 7.1% in the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock valued at $391,000 after acquiring an additional 799 shares during the period. Institutional investors own 46.93% of the company’s stock.
In related news, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $43.73, for a total transaction of $1,689,552.28. Following the transaction, the chief executive officer now owns 3,330,780 shares in the company, valued at approximately $145,655,009.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider K Peony Yu sold 15,000 shares of FibroGen stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $60.00, for a total transaction of $900,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 428,118 shares of company stock worth $22,355,896. 14.90% of the stock is owned by corporate insiders.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.